Lipoprotein(a) — Inherited Heart Risk and Your Genetics
Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder
Research base: Robust.
What is lipoprotein(a)?
Lipoprotein(a), abbreviated Lp(a), is a modified low-density lipoprotein particle defined by the covalent attachment of apolipoprotein(a) [apo(a)] to apolipoprotein B-100 via a disulfide bond. Unlike other lipoproteins, Lp(a) levels are largely genetically determined — they show very low intraindividual variation over time and are minimally affected by diet or lifestyle. About 70–90% of the variance in plasma Lp(a) concentration is heritable, making it one of the most genetically influenced quantitative traits in human biology.
Elevated Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD), myocardial infarction, stroke, and aortic valve stenosis. Lp(a) acts through multiple mechanisms: it competes with plasminogen for fibrin binding (potentially impairing fibrinolysis), carries oxidized phospholipids (which drive vascular inflammation), and contributes to lipoprotein-mediated cholesterol deposition in arterial walls. Current cardiovascular guidelines increasingly recommend measuring Lp(a) at least once in adults, particularly in those with premature cardiovascular disease or family history.
The genetics behind lipoprotein(a) levels
The genetic architecture of Lp(a) levels involves both the primary structural gene (LPA) and a broader network of lipid metabolism regulators. This GWAS dataset, drawn from multiple population studies, identifies 94 prioritized gene candidates spanning the lipoprotein metabolism pathway, placing Lp(a) genetics firmly within the broader genetic landscape of atherogenic lipoprotein biology.
The top-ranked genes by composite locus-to-gene scoring include:
APOE (Apolipoprotein E), ranked first (locus-to-gene score 0.964, high confidence), is the major determinant of triglyceride-rich lipoprotein remnant clearance. The three APOE isoforms (ε2, ε3, ε4) differentially affect plasma lipid concentrations including Lp(a). APOE ε4 is associated with elevated atherogenic lipoproteins broadly, while ε2 is generally protective. APOE variants affect lipoprotein receptor binding and uptake kinetics, influencing the metabolic fate of multiple lipid particles including those that share metabolic pathways with Lp(a).
APOH (Apolipoprotein H, also called Beta-2 glycoprotein I), ranked second (locus-to-gene score 0.971, high confidence), is a phospholipid-binding plasma protein that interacts with lipoprotein surfaces. APOH binds oxidized phospholipids carried by Lp(a) and may influence Lp(a) clearance kinetics, its pro-inflammatory properties, or its recognition by scavenger receptors on vascular macrophages. APOH is also a major autoantigen in antiphospholipid syndrome, highlighting its relevance at the lipid-inflammation interface.
HP (Haptoglobin), ranked third (locus-to-gene score 0.967, high confidence), is an acute-phase protein that binds free hemoglobin and facilitates its clearance. HP variants, particularly the HP1/HP2 copy number polymorphism, have been associated with cardiovascular risk in diabetic patients. Its genetic association with Lp(a) levels may reflect shared metabolic or inflammatory pathways, or linkage disequilibrium with nearby lipid-relevant loci.
APOB (Apolipoprotein B-100), ranked fourth (locus-to-gene score 0.960, high confidence), is the structural apolipoprotein of LDL and Lp(a). Every Lp(a) particle contains exactly one apoB-100 molecule. Variants in APOB affect the structure and function of both LDL and Lp(a), including their hepatic secretion rates and receptor binding properties.
PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9), ranked sixth (locus-to-gene score 0.955, high confidence), is a major regulator of LDL receptor surface expression. PCSK9 inhibitors (evolocumab, alirocumab) are approved for LDL-C reduction and also lower Lp(a) levels by 15–20%, suggesting that hepatic receptor-mediated Lp(a) uptake involves pathways regulated by PCSK9. Gain-of-function PCSK9 variants are associated with familial hypercholesterolemia and elevated Lp(a); loss-of-function variants reduce both LDL-C and Lp(a).
SORT1 (Sortilin 1), ranked seventh (locus-to-gene score 0.945, high confidence), is a multifunctional receptor in hepatocytes involved in VLDL secretion and LDL catabolism. The 1p13 locus containing SORT1 is one of the most significant genetic loci for LDL-C, CAD, and lipid-related traits. Its association with Lp(a) levels extends the pleiotropic role of this locus across the atherogenic lipoprotein spectrum.
CETP (Cholesteryl Ester Transfer Protein), ranked eighth (locus-to-gene score 0.929, high confidence), facilitates the exchange of cholesteryl esters and triglycerides between HDL and apoB-containing particles. CETP activity affects the composition and clearance of atherogenic lipoproteins broadly.
What the research says
The evidence base for Lp(a) genetics is one of the most extensively replicated in cardiovascular GWAS, drawing from nine independent studies spanning 2015–2024.
Jeon S et al. (2024) — GigaScience — PMID 38626723
"Korea4K: whole genome sequences of 4,157 Koreans with 107 phenotypes derived from extensive health check-ups." A large-scale Korean population whole-genome sequencing study with deep phenotyping across 107 traits including plasma lipoprotein(a) levels. This multi-phenotype study contributes to the cross-ancestry evidence base for Lp(a) genetics, complementing European-ancestry-dominant GWAS with East Asian population data.
Multi-study evidence base: Nine independent GWAS studies contribute to this trait's evidence (PMIDs spanning 2015–2024), collectively supporting 94 prioritized gene candidates and 113 filtered genes. The convergence of APOE, APOB, PCSK9, SORT1, and CETP — each a major node in the atherogenic lipoprotein network — across multiple studies provides robust cross-validation for the biological signal in Lp(a) genetics.
The convergence of multiple established lipid pathway genes in this dataset reflects the broad genetic architecture of Lp(a) levels beyond the primary LPA locus. These secondary genetic contributors regulate the metabolic context in which Lp(a) operates, including the lipoprotein metabolism machinery that affects Lp(a) clearance, modification, and atherogenic potency.
How lipoprotein(a) levels affect you
Elevated Lp(a) is one of the most prevalent and underrecognized inherited cardiovascular risk factors. At plasma concentrations above 50 mg/dL (or roughly 125 nmol/L), Lp(a) confers a cardiovascular risk equivalent to heterozygous familial hypercholesterolemia in magnitude. Unlike LDL-C, Lp(a) is minimally responsive to statins (statins can actually mildly increase Lp(a) in some individuals), making it a residual risk factor that persists even in well-treated patients.
Approved Lp(a)-lowering treatments are in late-stage development. PCSK9 inhibitors provide modest reductions (~15–20%). RNA-based therapeutics targeting LPA mRNA (pelacarsen, olpasiran, lepodisiran) are in Phase 3 trials and achieve >70–90% Lp(a) reduction, representing a potential therapeutic breakthrough for the estimated 1 in 5 people globally with elevated Lp(a).
Working with your variant profile
Because Lp(a) levels are so strongly genetically determined, knowing one's Lp(a) level directly (via a standard blood test) is more informative for cardiovascular risk assessment than genetic association data from GWAS. Major cardiology societies now recommend that Lp(a) be measured at least once in adults, particularly in those with premature cardiovascular disease, a family history of early-onset atherosclerosis, or residual cardiovascular risk despite statin therapy.
The genetic signals from ExomeDNA provide insight into the broader lipoprotein biology influencing Lp(a) levels and related metabolic traits, but direct Lp(a) measurement is the clinical standard for cardiovascular risk stratification.
Related traits and genes
Lipoprotein(a) levels are genetically correlated with LDL cholesterol, coronary artery disease, aortic stenosis, and stroke. APOE overlaps with Alzheimer's disease genetics; PCSK9 is a major target for LDL-lowering therapy; SORT1 is one of the most significant CAD GWAS loci; CETP has been a target for HDL-raising drug development. The LPA gene itself (the primary structural determinant of Lp(a) levels) is captured in a separate trait entry with a focused early-studies evidence base.
Frequently asked questions
Why do APOE and PCSK9 appear in Lp(a) genetics?
APOE affects the clearance of atherogenic lipoprotein remnants including those metabolically related to Lp(a), and different APOE isoforms modulate overall lipid levels including Lp(a). PCSK9 regulates hepatic LDL receptor abundance, and LDL receptors mediate some Lp(a) clearance — loss-of-function PCSK9 variants reduce both LDL-C and Lp(a). PCSK9 inhibitors also lower Lp(a) by ~15–20% in clinical practice, confirming this pathway's relevance.
Why is Lp(a) so strongly heritable?
The plasma Lp(a) concentration is determined primarily by the transcription rate of the LPA gene and by the number of KIV-2 kringle domain repeats encoded in the LPA locus — a copy number variant that is tightly heritable and resistant to environmental modification. Unlike LDL-C, which responds substantially to diet, statins, and lifestyle, Lp(a) levels remain remarkably stable within individuals over time, reflecting their predominantly genetic determination.
Is Lp(a) the same as LDL cholesterol?
No. Lp(a) is a structurally distinct lipoprotein particle: it contains apoB-100 (like LDL) but also carries a covalently attached apo(a) chain with plasminogen-like kringle domains. The apo(a) component gives Lp(a) unique properties — it carries oxidized phospholipids, can interfere with fibrinolysis, and is not cleared by the same pathways as LDL. Statins, which dramatically reduce LDL-C, have minimal effect on Lp(a) levels.
What does APOH (Beta-2 glycoprotein I) do in lipoprotein biology?
APOH binds phospholipids on lipoprotein surfaces and in the plasma. It associates with Lp(a) particles through binding to the oxidized phospholipids carried on the apo(a) chain. APOH may influence how Lp(a) interacts with vascular surfaces, immune cells, and scavenger receptors, potentially modulating its atherogenic and pro-inflammatory properties. APOH is also a major autoantibody target in antiphospholipid syndrome, a thrombotic autoimmune disorder with cardiovascular implications.
Should Lp(a) be measured directly or estimated from genetics?
Direct measurement (standard blood test) is strongly preferred for clinical decision-making. Lp(a) testing is inexpensive, widely available, and far more precise than genetic risk scoring for this trait. Most cardiology guidelines now recommend at least one lifetime Lp(a) measurement in adults, particularly before starting preventive cardiovascular therapy. Genetic associations from GWAS provide biological context but do not replace direct quantification for risk assessment.